CYP2C9*1*2 and VKORC1-1639 AA Polymorphisms Correlation with Warfarin Dose Requirement: A Case Report

Zohreh Hoseinkhani; Reza Khodarahmi; Mona Sadeghalvad; Fathemeh Norooznezhad; Kamran Mansouri

Outlines

Abstract
Copyright

CYP2C912 and VKORC1-1639 AA Polymorphisms Correlation with Warfarin Dose Requirement: A Case Report

Author(s):

Zohreh Hoseinkhani¹,

Reza Khodarahmi¹,

Mona Sadeghalvad¹,

Fathemeh Norooznezhad¹,

Kamran Mansouri^1,*

1Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Journal of Reports in Pharmaceutical Sciences:Vol. 7, issue 1; 88-91

Published online:Dec 25, 2017

Article type:Case Report

Received:Nov 17, 2017

Accepted:Dec 15, 2017

How to Cite:Zohreh HoseinkhaniReza KhodarahmiMona SadeghalvadFathemeh NorooznezhadKamran MansouriCYP2C9*1*2 and VKORC1-1639 AA Polymorphisms Correlation with Warfarin Dose Requirement: A Case Report.J Rep Pharm Sci.7(1):e147605.

Abstract

CYP2C9 and VKORC1-1639 G>A genes as the genetic factors significantly influence the warfarin dose requirement in individuals. The patients with genetic variations in CYP2C9 and VKORC1 are at increased risk of adverse warfarin-related events. A young patient with atrial septal defect being highly sensitive to normal daily dose of warfarin was subjected to the study. The patient consented to genetic testing. Furthermore, DNA was isolated and PCR-RFLP performed. The patient required low warfarin dose of 11 mg/week to achieve the target international normalized ratio (INR). Genetic testing revealed that the patient carried VKORC1-1639 AA and CYP2C9*1*2 genotypes. Our findings reaffirm the significance of pharmacogenetic analysis prior to the warfarin therapy to achieve an efficient treatment and the least side/adverse drug effects.

Keywords

Warfarin

International normalized ratio

VKORC1 genotype

CYP2C9 genotype

comments